Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ADT, Darolutamide, and Pembrolizumab in High-Risk Prostate Cancer
NCT07027124Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, darolutamide in prostate cancer (PCa), sponsored by Icahn School of Medicine at Mount Sinai. Started May 2026; status: recruiting.
02
Drugs
pembrolizumabdarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07027124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027124.